<code id='850565BA8F'></code><style id='850565BA8F'></style>
    • <acronym id='850565BA8F'></acronym>
      <center id='850565BA8F'><center id='850565BA8F'><tfoot id='850565BA8F'></tfoot></center><abbr id='850565BA8F'><dir id='850565BA8F'><tfoot id='850565BA8F'></tfoot><noframes id='850565BA8F'>

    • <optgroup id='850565BA8F'><strike id='850565BA8F'><sup id='850565BA8F'></sup></strike><code id='850565BA8F'></code></optgroup>
        1. <b id='850565BA8F'><label id='850565BA8F'><select id='850565BA8F'><dt id='850565BA8F'><span id='850565BA8F'></span></dt></select></label></b><u id='850565BA8F'></u>
          <i id='850565BA8F'><strike id='850565BA8F'><tt id='850565BA8F'><pre id='850565BA8F'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:Wikipedia    Page View:79
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In